Korro Bio, Inc.
Korro Bio is a biopharmaceutical company developing RNA-editing medicines for rare and highly prevalent diseases. Its OPERA platform uses engineered oligonucleotides to recruit the body’s ADAR enzymes and make targeted, transient edits to RNA. Korro aims to use these edits to repair or activate protein pathways rather than silence genes. Its wholly owned programs include KRRO-121 for hyperammonemia, a GalNAc-conjugated program to repair the alpha-1 antitrypsin protein in people with AATD, a GalNAc-conjugated program targeting the AMPKγ1 pathway for longevity and liver health, and an ALS program using intrathecal delivery. Korro’s medicines are in research or preclinical development. It also has up to two programs partnered with Novo Nordisk. The company is headquartered in Cambridge, Massachusetts.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $KRRO in the last 7 days.
FORMELA JEAN FRANCOIS sold 66,632 indirectly-held shares of Korro Bio, Inc. (KRRO) at an average of $14.61 ($14.30–$15.60, $0.97M total) across 6 trades over 2026-11-11 to 2026-11-12 under a Rule 10b5-1 trading plan.
Korro Bio (KRRO) announced that Novo Nordisk (NVO) will terminate their research collaboration and license agreement, effective February 1, 2027. The agreement, which covered cardiometabolic compounds, was paused in 2025. Korro received a $10M upfront payment but no milestone payments. Post-termination, both parties will retain their respective intellectual property. Korro expects to focus on its rare-disease programs, with key milestones in 2027.
Korro Bio reported no revenue in Q3 2026, down from $1.1M a year earlier, with a net loss of $17.55M, a 2.8% improvement. EPS loss narrowed to $0.98. R&D costs fell to $12.1M. KRRO-121 trial dosing began, and KRRO-111 submission is expected in 2027. Cash runway extends to mid-2028, according to the company.
Recent KRRO coverage spans financial news, insider activity and earnings.
In the last 30 days, KRRO insiders filed 10 SEC Form 4 transactions — 4 purchases ($885K) and 6 sales ($974K). The most active reporter was FORMELA JEAN FRANCOIS with 6 filings. 60% of those filings were made under pre-arranged Rule 10b5-1 plans.
The insider sale may signal reduced confidence and could pressure the stock price.
Negative impact as Korro loses potential future payments and partnership support.
Earnings miss with zero revenue but loss improvement; small‑cap biotech likely faces continued downside pressure.
The company disclosed new cash position, trial progress, and regulatory designation, which could affect its valuation.
Buy may reinforce bullish momentum.
AlphAI scores every news story that mentions KRRO with an AI model for sentiment and relevance, and aggregates insider trades from Korro Bio, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
FORMELA JEAN FRANCOIS sold 66,632 indirectly-held shares of Korro Bio, Inc. (KRRO) at an average of $14.61 ($14.30–$15.60, $0.97M total) across 6 trades over 2026-11-11 to 2026-11-12 under a Rule 10b5-1 trading plan.
Korro Bio (KRRO) announced that Novo Nordisk (NVO) will terminate their research collaboration and license agreement, effective February 1, 2027. The agreement, which covered cardiometabolic compounds, was paused in 2025. Korro received a $10M upfront payment but no milestone payments. Post-termination, both parties will retain their respective intellectual property. Korro expects to focus on its rare-disease programs, with key milestones in 2027.
Korro Bio reported no revenue in Q3 2026, down from $1.1M a year earlier, with a net loss of $17.55M, a 2.8% improvement. EPS loss narrowed to $0.98. R&D costs fell to $12.1M. KRRO-121 trial dosing began, and KRRO-111 submission is expected in 2027. Cash runway extends to mid-2028, according to the company.
Korro Bio, Inc. (KRRO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Korro Reports Third Quarter 2026 Financial Results and Provides Corporate Update — Started dosing healthy volunteers with KRRO-121 in the Phase 1/2 clinical trial (ANCHOR) o Expect to dose participants with Urea Cycle Disorders (UCDs) in the first half of 2027 o Anti
Group 1 Automotive (GPI) saw a $24.2M insider purchase by Conifer Management, while Corebridge Financial (CRBG) had an $8.7M buy by Nippon Life. Optimum Communications (OPTU) and Korro Bio (KRRO) also reported insider buys. Gentherm (THRM) had a $532.6K purchase. On the sell side, Intuitive Surgical (ISRG), Charles River Labs (CRL), Lam Research (LRCX), United Therapeutics (UTHR), and PACS Group (PACS) reported insider sales.
Lynx1 Capital Management LP purchased 79,809 indirectly-held shares of Korro Bio, Inc. (KRRO) at an average of $11.09 ($9.68–$12.11, $0.88M total) across 4 trades over 2026-10-22 to 2026-10-26. Filed jointly with Nichols Weston (10% owner).
Biohaven (BHVN) +31% after FDA accepted resubmitted drug application for spinocerebellar ataxia. Korro Bio (KRRO) +25% on positive preclinical results for AATD treatment. Actinium (ATNM) +18% with initial Phase 1 data for prostate cancer radiotherapy. Vicore (VCRE) +16% after passing IPF trial futility analysis.
Korro Bio reported preclinical results for KRRO-111, showing potential to treat lung and liver manifestations of alpha-1 antitrypsin deficiency. The company expects to submit a regulatory filing for KRRO-111 in the first half of 2027. Key findings include 96% mRNA editing and significant reduction in liver Z-AAT.
Korro Bio, Inc. (KRRO) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Korro Reports Best-in-Class Preclinical Data for KRRO-111 Demonstrating Potential to Benefit Lung and Liver Manifestations of Alpha-1 Antitrypsin Deficiency • Repeat dose mouse studies achieved >95% SERPINA1 mRNA editing, sustained restoration of circulating function
H.C. Wainwright reiterated a Buy rating and $15.00 price target for Korro Bio (KRRO) after the company dosed the first cohort in its Phase 1/2 trial for KRRO-121. The stock is down 77% over the past year, trading at $9.97. Korro Bio has a strong current ratio of 9.55 and more cash than debt. The ANCHOR trial is expected to take about a year, with primary completion estimated for the second half of 2027.
